<DOC>
	<DOCNO>NCT01053910</DOCNO>
	<brief_summary>The objective investigate safety ramipril 10 mg/day use prevention cardiovascular event high-risk patient , include criterion HOPE study .</brief_summary>
	<brief_title>Ramipril 10 mg/Day Prevention</brief_title>
	<detailed_description />
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Ramipril</mesh_term>
	<criteria>History coronary artery disease , Stroke Stable heart failure Peripheral vascular disease , diabetes least one cardiovascular risk factor ( hypertension , elevate total cholesterol level , low highdensity lipoprotein cholesterol level , cigarette smoking , document microalbuminuria ) . Non stabilize NYHA grade IV heart failure patient Hemodynamically significant primary valvular outflow tract obstruction ( eg . mitral valve stenosis , asymmetric septal hypertrophy , malfunction prosthetic valve ) Constrictive pericarditis . Complex congenital heart disease . Syncopal episodes presume due uncontrolled lifethreatening arrhythmia ( asymptomatic cardiac arrhythmia include ventricular tachycardia exclusion criterion ) . Planned cardiac surgery angioplasty within 3 month ( patient may reconsider trial procedure ) . Cor pulmonale . Heart transplant recipient . Significant renal disease define : Renal artery stenosis ; Creatine clearance &lt; 0.6 ml/second serum creatinine≥ 200 mEq/L ( ≥2.26 mg/dl ) Overt nephropathy : ≥1 plus proteinuria dipstick urinary albumin excretion &gt; 200 micrograms/minute ( 300 mg/24 hr ) Hyperkalemia ; K &gt; 5.5 mEq/L . Patient simultaneously take another experimental drug . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
</DOC>